Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Job Seekers With Disabilities Face Discrimination At Application Stage, UK
In a snapshot survey published by Terrence Higgins Trust today, two thirds of top organisations were found to ask irrelevant health related questions on job application forms. A coalition of charities wants these questions banned to reduce the discrimination faced by people with "invisible" conditions such as mental illness or HIV.
generic viagra online
BMA Scotland Chairman Urges MSPs Not To Play Politics With Public Health
Speaking at the Annual Conference of the British Medical Association (BMA), Dr Peter Terry, chairman of the BMA Scotland urged MSPs to put party politics aside and stand together to improve health. He also underlined the need for legislation on the price of alcohol as an effective measure to tackle Scotland"s drink problem.
News of the day
Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Ascenta Therapeutics announced that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
Sexual Health

POZEN Receives Decision From AstraZeneca To File PN 400 NDA

POZEN Inc. (NASDAQ: POZN) reported that AstraZeneca has made the decision to have POZEN file the New Drug Application (NDA) for PN 400 with the United States Food and Drug Administration (FDA). POZEN continues to target a mid-2009 NDA filing and expects to receive a milestone payment of $10 million when the NDA is formally accepted for submission by the FDA. The license agreement executed with AstraZeneca in August 2006 established a Phase III clinical development program for PN 400, an investigational compound, that combines the pain reliever naproxen (an NSAID) with esomeprazole magnesium, a proton pump inhibitor (PPI), to support a potential indication for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers. POZEN Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009